Tag Archives: R&D

Tough Times Ahead for New Medicines under NHS England?

By Leela Barham You’d be forgiven for missing it with the vast array of new agencies and the policy documents, guidance, consultations and ‘engagement’ activity they’re doing on in the ‘new’ NHS in England, but on the 4th April NHS England (formerly the NHS Commissioning Board) set out 15 commissioning policies in 250 pages.  They’re […]
Posted in Europe, Global, Guest Blog, healthcare, pricing | Also tagged , , , , | Leave a comment

Emerging Countries' R&D: A Contest, but No Wipe Out

Emerging country markets are widely viewed as Big Pharma’s ace in the hole to replace declining rates of innovation in the US and Europe, with numerous studies claiming the BRICK nations (the ‘K’ is from South Korea) are at the center of a revolutionary global shift in the source points for new ideas —  what […]
Posted in Emerging Markets, Global, IP, R&D | Also tagged , , | 2 Comments

Getting it Done in Washington

During his fifth State of the Union address, President Obama struck many familiar chords – including a line about ending certain subsidies to pharmaceutical companies – and emphasized, repeatedly, the need to get things done on the policy front. Will the sequestration drum beat goad members of the 113th Congress onto the dance floor?
Posted in healthcare, Legal, pricing, R&D, Strategy | Also tagged , , , , , , | Leave a comment

Pharma's Shifting Needs for Scientific Talent

By Susan Haigney. Developing and maintaining the right labor pool is an ongoing challenge for any industry, and it is one that the pharmaceutical industry also is facing. Recent attention in the pharmaceutical industry has focused on the restructuring that has occurred and that is still occurring among the large pharmaceutical companies. And while re-allocating […]
Posted in Guest Blog | Also tagged , | Leave a comment

Will "Robust Pipeline" Yield More New Drugs?

Biopharmaceutical companies are touting their huge investment in R&D, which has filled the drug pipeline with more potential first-in-class medicines, including orphan drugs, personalized medicines and new therapies based on novel scientific strategies. A report by the Analysis Group for the Pharmaceutical Research and Manufacturers of America (PhRMA) documents more than 5,000 new medicines in […]
Posted in Biotech, FDA, leadership, R&D, Regulatory | Also tagged , , , , , | Leave a comment
  • Categories

  • Meta